Roelcke U, Leenders K L
PET Program, Paul Scherrer Institute, Villigen, Switzerland.
J Cancer Res Clin Oncol. 2001 Jan;127(1):2-8. doi: 10.1007/s004320000158.
This article reviews possible clinical applications of positron emission tomography (PET) in brain tumor patients. PET allows quantitative assessment of brain tumor pathophysiology and biochemistry. It therefore provides different information about tumors when compared to histological or neuroradiological methods. Common clinical indications for PET comprise tumor delineation and identification of the metabolically most active tumor regions (target for biopsy, differentiation of viable tumor from necrosis). Further, the spatial relation between brain activated e.g., by speech, and the tumor bulk can be explored by activation studies. PET could also aid in the prediction of treatment response by measurement of tumor perfusion or hypoxia. Moreover, PET tracers could identify treatment targets e.g., gene products. The latter topic has not been systematically evaluated in human patients.
本文综述了正电子发射断层扫描（PET）在脑肿瘤患者中的可能临床应用。PET能够对脑肿瘤的病理生理学和生物化学进行定量评估。因此，与组织学或神经放射学方法相比，它能提供有关肿瘤的不同信息。PET常见的临床适应证包括肿瘤的勾勒以及确定代谢最活跃的肿瘤区域（活检靶点、区分存活肿瘤与坏死灶）。此外，通过激活研究可以探索例如由言语激活的脑区与肿瘤体积之间的空间关系。PET还可以通过测量肿瘤灌注或缺氧情况来辅助预测治疗反应。此外，PET示踪剂可以识别治疗靶点，例如基因产物。后一主题尚未在人类患者中进行系统评估。
